Join the Colorectal Cancer group to help and get support from people like you.
Colorectal Cancer News (Page 8)
Related terms: Cancer, Anal, Cancer, Colon, Cancer, Colorectal, Cancer, Rectal, Colon Cancer, Colon Carcinoma, Colorectal Carcinoma, Rectal Cancer
Opdivo (nivolumab) + Low-Dose Yervoy (ipilimumab) Combination Approved for Previously Treated MSI-H/dMMR Metastatic Colorectal Cancer
PRINCETON, N.J.-- July 11, 2018 (BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced Opdivo (nivolumab) 3 mg/kg plus low-dose Yervoy (ipilimumab) 1 mg/kg (injections for...
FDA Approves Mvasi (bevacizumab-awwb), a Biosimilar to Avastin
September 14, 2017 – The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is...
Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in MSI-H or dMMR Metastatic Colorectal Cancer That Has Progressed Following Treatment
PRINCETON, N.J.--(BUSINESS WIRE) August 1, 2017 – Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection for...
FDA Approves Lonsurf (tipiracil and trifluridine) for Advanced Colorectal Cancer
September 22, 2015 – The U.S. Food and Drug Administration today approved Lonsurf (a pill that combines two drugs, trifluridine and tipiracil) for patients with an advanced form of colorectal cancer...
FDA Approves Cyramza (Ramucirumab) for Use with FOLFIRI in Second-Line Treatment of Metastatic Colorectal Cancer
INDIANAPOLIS, April 24, 2015 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) has received its fourth U.S. Food and Drug Administration (FDA) approval for Cyramza (ramucirumab). Cyramza (ramucirumab...
Ask a question
To post your own question to this support group, sign in or create an account.